Last $238.84 USD
Change Today -0.06 / -0.03%
Volume 428.2K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 2:47 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$240.00
Previous Close
$238.90
Day High
$240.96
Day Low
$237.95
52 Week High
09/26/14 - $264.98
52 Week Low
04/15/14 - $141.66
Market Cap
47.0B
Average Volume 10 Days
685.0K
EPS TTM
--
Shares Outstanding
196.7M
EX-Date
03/11/15
P/E TM
--
Dividend
$1.15
Dividend Yield
0.26%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc-adr (SHPG) Key Developments

Shire plc Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults

Shire plc announced that the company has submitted a New Drug Application (NDA) with the U. S. Food and Drug Administration for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. The NDA submission is supported by the totality of evidence from four clinical trials with more than 1,800 patients. These included one Phase 2 study, two Phase 3 efficacy and safety studies, and one long-term Phase 3 safety study.

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

Shire plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 11:15 AM

Shire plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 11:15 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Gary Clements, Head of Research Alliances.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $238.90 USD 0.00

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$92.18 AUD +0.38
Eisai Co Ltd ¥6,283 JPY +33.00
Hospira Inc $87.79 USD +0.08
Mylan NV $55.45 USD +0.015
UCB SA €68.24 EUR +0.85
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 14.3x
Price/Sales 7.7x
Price/Book 5.4x
Price/Cash Flow 13.7x
TEV/Sales 7.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.